$CTMX

Barclays Raises its Price Target on CytomX Therapeutics, Inc. (CTMX) to $10 and Maintains an Overweight Rating

Barclays has increased its price target for CytomX Therapeutics, Inc. (CTMX) to $10 from $8 while maintaining an Overweight rating, following a similar move by Piper Sandler and new coverage initiation by Guggenheim with a Buy rating, both also setting a $10 price target. The positive outlook is primarily driven by promising Phase I data on varsetatug maseatecan, which demonstrated significant anti-tumor activity in metastatic colorectal cancer patients. CytomX is expected to provide further updates on its expansion cohorts soon.

Original reporting
Yahoo Finance UK · Jeff Lewis
Published Feb 17, 2026, 10:02 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Feb 17, 2026, 11:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Barclays Raises its Price Target on CytomX Therapeutics, Inc. (CTMX) to $10 and Maintains an Overweight Rating — source image
Decision brief

The 30-second read

$CTMXBullishMed
01

Why it matters

The recent upgrade and positive trial results are likely to boost investor confidence and could lead to short-term stock appreciation.

02

Market read

The biotech sector is currently experiencing increased investor interest, and positive clinical data can serve as a catalyst for stock movements.

03

What to watch

Potential delays in clinical trial results or regulatory hurdles could negatively impact stock performance.

Timing: Immediate to short-term (next 1-3 weeks)

Background

CytomX Therapeutics, Inc. is a biotech firm specializing in targeted cancer therapies. Recent analyst upgrades and promising clinical data have increased investor interest.

Company-level read

Ticker impact

$CTMXBullishHigh confidence
Context

High relevance due to recent analyst upgrade and promising clinical data.

Expected impact

Potential increase of 10-15% in the near term, contingent on market reaction and broader biotech sector performance.

Evidence & confidence

Multiple analyst upgrades and promising clinical trial results support a bullish outlook, with high confidence given the recent positive catalysts.

Market effects

Positive impact on biotech and life sciences sectors, especially companies involved in oncology and clinical trials.

Primarily US-based biotech sector, with potential ripple effects in European markets due to global investor interest.

Moderate; biotech sector is influential but subject to broader market conditions.

Counterpoint

The positive data may be priced in already, and sector rotation or profit-taking could lead to short-term pullback.

Key entities

  • CytomX Therapeutics, Inc.

    Biotech company focusing on targeted cancer therapies.

  • Barclays

    Investment bank that upgraded CTMX's price target.

  • Phase I data on varsetatug maseatecan

    Promising early-stage clinical results showing anti-tumor activity.

Related articles

$CTMXMed

CytomX Therapeutics, Inc. (CTMX): Results of Operations and Financial Condition

CytomX Therapeutics, Inc. (CTMX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ctmx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update Varsetatug masetecan (“Varseta-M”) Program: - Phase 1 monotherapy update in advanced colorectal cancer (CRC) expected by the end of 2026. Re

$WIAMedAI 8/10

Wia Gold lines up $360m deal for Kokoseb project

WIA Gold said it signed indicative terms with Sprott Resource Lending to arrange $360m in construction debt for its Kokoseb gold project in Namibia, plus Sprott’s planned $15m purchase of WIA scrip in a future equity raise, subject to due diligence. WIA reported a definitive feasibility study forecasting 150,000 oz/y, 1.84m oz over 14 years, with $475m total capex and a 29% higher resource to 3.78m oz, using a $3,600/oz gold price.

$BAMedAI 9/10

Boeing Receives $75M Air Force Contract Action

Boeing said the U.S. Air Force awarded a $75 million undefinitized contract action to start initial production of the BSU-111/B payload delivery unit for the JDAM LR (GBU-75). Boeing said initial deliveries will go to the U.S. Navy. The BSU-111/B adds a wing-and-engine kit to extend range beyond 300 nautical miles, according to Boeing.

$TSNMed

Taylor Farms recalls jalapeno products after salmonella outbreak

Taylor Farms is recalling about 20 fresh jalapeno-containing products, including dips, sandwiches, guacamole and sliced jalapenos, across 26 US states after a salmonella outbreak. The company said it has not identified illnesses linked to the products, but traced the source to a grower in Sinaloa, Mexico, and is switching suppliers. Retailers include Walmart, Target and Whole Foods.

$LMTMed

Pentagon Presses for Weapons Surge as Iran War Drains U.S. Stockpiles

The Pentagon is pressing weapons makers to accelerate production after U.S. missile shortages tied to the Iran war. CSIS analysis says Patriot interceptor stocks fell from about 2,330 to 759-827, and THAAD from about 452 to 234-278. Reuters reports the Army used “virtually all” ATACMS and PrSM. The Pentagon is awarding contracts with Lockheed Martin and Northrop Grumman.

$BKRMed

Baker Hughes to supply subsea systems for Indonesia's Kutei Northern Hub

Baker Hughes said it won a contract from Searah North Ganal Ltd., a JV of Eni and PETRONAS, to supply subsea production systems and digital technologies for Indonesia’s Kutei Northern Hub gas project. It will provide 17 deepwater horizontal subsea trees plus manifolds, controls and distribution equipment, and use its Cordant monitoring platform. The hub targets LNG and gas output from Geng North and Gehem fields.